磁共振引导立体定向体部放疗再照射治疗局部复发前列腺癌:一项多中心回顾性分析
这项多中心回顾性分析纳入18例既往接受外照射放疗后局部复发的前列腺癌患者,采用0.35 T混合磁共振引导的立体定向体部放疗进行再照射,总剂量25–40 Gy分5次。4例(22.2%)达完全缓解,未记录≥2级急性泌尿生殖毒性,4例(22.2%)发生急性胃肠道毒性。作者认为急性毒性发生率低,鼓励将磁共振引导立体定向体部放疗视为临床复发前列腺癌的可行治疗方式。
要点
- 18例局部复发前列腺癌患者接受0.35 T磁共振引导SBRT再照射,总剂量25–40 Gy分5次。
- 完全缓解4例(22.2%),未记录≥2级急性泌尿生殖毒性,急性胃肠道毒性4例(22.2%)。
- 作者认为急性毒性低,鼓励将磁共振引导SBRT视为临床复发前列腺癌的可行治疗方式。
核心结论
- 作者认为该经验中急性毒性发生率低,鼓励将磁共振引导SBRT视为临床复发前列腺癌的可行治疗方式。
- 作者指出靶区精确门控、在线自适应计划流程和高清MRI治疗图像可在高效保护危及器官的同时向PTV递送高剂量。
研究设计与样本
- 多中心回顾性分析,纳入2019年至2022年在五家机构治疗的局部复发前列腺癌患者。
- 所有患者既往接受过根治性或辅助性放疗,再治疗采用0.35 T混合磁共振引导SBRT,总剂量25–40 Gy分5次。
- 共纳入18例患者,所有患者既往接受外照射放疗总剂量59.36–80 Gy。
- 按CTCAE v5.0评估毒性,在治疗结束时和随访时评估治疗反应。
主要发现
- 完全缓解4例(22.2%)。
- 未记录≥2级急性泌尿生殖毒性事件,急性胃肠道毒性事件4例(22.2%)。
临床怎么用
- 作者认为磁共振引导SBRT是临床复发前列腺癌的可行治疗方式,依据为急性毒性发生率低。
- 作者指出靶区精确门控、在线自适应计划流程和高清MRI治疗图像有助于在保护危及器官的同时向PTV递送高剂量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Reirradiation of prostate cancer (PC) local recurrences represents an emerging challenge for current radiotherapy. In this context, stereotactic body radiation therapy (SBRT) allows the delivery of high doses, with curative intent. Magnetic Resonance guided Radiation Therapy (MRgRT) has shown promising results in terms of safety, feasibility and efficacy of delivering SBRT thanks to the enhanced soft tissue contrast and the online adaptive workflow. This multicentric retrospective analysis evaluates the feasibility and efficacy of PC reirradiation, using a 0.35 T hybrid MR delivery unit. METHODS: Patients affected by local recurrences of PC and treated in five institutions between 2019 and 2022 were retrospectively collected. All patients had undergone previous Radiation Therapy (RT) in definitive or adjuvant setting. Re-treatment MRgSBRT was delivered with a total dose ranging from 25 to 40 Gy in 5 fractions. Toxicity according to CTCAE v 5.0 and treatment response were assessed at the end of the treatment and at follow-up. RESULTS: Eighteen patients were included in this analysis. All patients had previously undergone external beam radiation therapy (EBRT) up to a total dose of 59.36 to 80 Gy. Median cumulative biologically effective dose (BED) of SBRT re-treatment was 213,3 Gy (103,1-560), considering an α/β of 1.5. Complete response was achieved in 4 patients (22.2%). No grade ≥ 2 acute genitourinary (GU) toxicity events were recorded, while gastrointestinal (GI) acute toxicity events occurred in 4 patients (22.2%). CONCLUSION: The low rates of acute toxicity of this experience encourages considering MRgSBRT a feasibile therapeutic approach for the treatment of clinically relapsed PC. Accurate gating of target volumes, the online adaptive planning workflow and the high definition of MRI treatment images allow delivering high doses to the PTV while efficiently sparing organs at risk (OARs).
引用
- Boldrini L, Romano A, Chiloiro G, et al. Magnetic resonance guided SBRT reirradiation in locally recurrent prostate cancer: a multicentric retrospective analysis. Radiat Oncol. 2023. PMID: 37218005. doi:10.1186/s13014-023-02271-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。